Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31. - Wikidata - awgldk - TriplyDB

Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31.

Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31.

http://www.wikidata.org/entity/Q37360367

about

Quantification of HER family receptors in breast cancer Statistical controversies in clinical research: prognostic gene signatures are not (yet) useful in clinical practice Meta-STEPP: subpopulation treatment effect pattern plot for individual patient data meta-analysis.Impact of hormone receptor status and distant recurrence-free interval on survival benefits from trastuzumab in HER2-positive metastatic breast cancer.Robust estimation of the expected survival probabilities from high-dimensional Cox models with biomarker-by-treatment interactions in randomized clinical trials.MicroRNA-940 suppresses prostate cancer migration and invasion by regulating MIEN1.Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial.Cytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant basal-HER2 subtype of breast cancer.The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831.Development of a test that measures real-time HER2 signaling function in live breast cancer cell lines and primary cells.SERPINA1 is a direct estrogen receptor target gene and a predictor of survival in breast cancer patients.Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration Luminal B breast cancer subtype displays a dicotomic epigenetic pattern HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients "Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome.High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy.Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.Pharmacometabolomics study identifies circulating spermidine and tryptophan as potential biomarkers associated with the complete pathological response to trastuzumab-paclitaxel neoadjuvant therapy in HER-2 positive breast cancer.HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status.Discordance between original and central laboratories in ER and HER2 results in a diverse, population-based sample.Subpopulation Treatment Effect Pattern Plot (STEPP) analysis for continuous, binary, and count outcomes.HER2-positive breast cancer is lost in translation: time for patient-centered research.BRAF, KRAS and PIK3CA Mutation and Sensitivity to Trastuzumab in Breast Cancer Cell Line Model Resistance to Targeted Therapies in Breast Cancer.IGF1R Protein Expression Is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2+ Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831.Predictive biomarkers in the treatment of HER2-positive breast cancer: an ongoing challenge.The assessment of HER2 status in breast cancer: the past, the present, and the future.Identification of biomarker-by-treatment interactions in randomized clinical trials with survival outcomes and high-dimensional spaces.'Non-classical' HER2 FISH results in breast cancer: a multi-institutional study.Prognostic significance of equivocal human epidermal growth factor receptor 2 results and clinical utility of alternative chromosome 17 genes in patients with invasive breast cancer: A cohort study.Breast carcinomas with low amplified/equivocal HER2 by Ish: potential supporting role of multiplex ligation-dependent probe amplification.Immune Signature to Predict Trastuzumab Benefit: Potential and Pitfalls.Tumor Uptake of 64Cu-DOTA-Trastuzumab in Patients with Metastatic Breast Cancer.Predicting the Efficacy of HER2-Targeted Therapies: A Look at the Host.Protective effect of naturally occurring anti-HER2 autoantibodies on breast cancer.MiR-205 as predictive biomarker and adjuvant therapeutic tool in combination with trastuzumab.Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform

P2860

Q27015506-DC16D179-A076-4C46-BA09-F79EEF247F63 Q28078729-CBC90C49-6EF4-49CA-BD2A-0A7C31B86733 Q31075630-EA2650F0-7BD5-49B1-B311-A11141654837 Q33683344-E12EA950-CAAD-40FF-889A-3B9CF6469994 Q33717226-5F0A39B1-F7CC-44C5-80EE-2987538DB61C Q34582195-6E367354-C999-4A53-913F-414C2CF53774 Q35102480-8944F287-0AB0-4DE3-AC54-89746DA60022 Q35419840-4CC0B93C-3DD3-4828-AB04-DC588F6AE090 Q35740160-08554B53-E7D7-44E0-B2D5-3E8DF16B3762 Q36110190-1A588842-FA47-4986-A82C-2875792488F1 Q36311216-2A33DE99-A81C-43FA-994F-EF49B9A0A00D Q36413297-BB3E53F6-7663-4B3C-8C42-07D7D187E206 Q36414012-DA9452FB-7DDD-463E-8B5B-43544F8CF724 Q36910353-5C5964E5-3CF0-4073-BBA0-34AB57A1CF02 Q37075632-2202370E-E5FF-43A5-A120-72F32EE55D5E Q37109643-BAFEEBAE-CF8C-493A-8533-5772CCC55887 Q37142882-29FA6D5F-7801-4105-88BF-6BF4F27D31DE Q37166436-7EA440C0-BCE5-445A-8017-871F60D4C88A Q37457684-B05084F1-4CED-4F41-95A8-907765EA1861 Q37588232-BC7C9226-205F-481E-A373-064C0C2EB1F0 Q38377039-E339EC80-106C-4445-B588-171975709C3A Q38380910-722CB794-BD79-4B61-A265-6BB3CC935ADC Q38648765-2006DCC4-7110-43FE-93C0-45E16BBA0132 Q38694128-B9736C87-3CBB-46E1-8C9D-0CBEAAD104D8 Q38748114-65770E1D-D37E-46F6-944D-808A458981FC Q38770018-121CA7B9-FECE-4B7B-991E-8AAEBA75BC8F Q38786102-734133F0-BEB2-48B8-B2E1-752B6189AD98 Q38802932-97C92FA8-3114-4329-BF84-C957E0B65A3F Q39175273-2A1CB6EA-B3FC-4D27-B4D6-F2585D2FB66E Q39292642-8EFCBA50-FB28-45C1-8750-AF1D196AE765 Q40453735-A71B2DB9-310E-4D33-BC50-1262785CD3DA Q42377436-25A8CFEF-2C24-460E-A8D2-55AFC4EEE432 Q42923134-728D5153-7562-4346-9A64-6B2E92E61303 Q47573583-ED1D8B5B-6119-4849-B274-5E83E502D611 Q48102534-C71B08B3-DABA-49C0-BDD7-A1F2D26BFC44 Q54198584-5CF4FD2D-B4FA-45F3-8CDC-C5166BC1CAE3 Q55374436-6C7203F8-F7F4-4EA9-9184-EC8C1E8B499B Q58767252-BD4A7BB7-BF28-4927-B60A-BA90D920AAC2

P2860

Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31.

http://www.wikidata.org/entity/Q37360367

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31.

@en

Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31.

@nl

type

label

Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31.

@en

Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31.

@nl

prefLabel

Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31.

@en

Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31.

@nl

P1433

Q37360367-AB41BA45-E20E-4450-B1AF-B6B3356135F7

P1476

Q37360367-615C390F-BC48-41EA-A2F0-BCDAB1EAD8B4

P2093

Q37360367-0EFC6225-FA3D-4164-9DC6-5535F9F37A82

Q37360367-2B8C70A5-E4E1-4AA1-8F4A-FFD20DBAF071

Q37360367-3238758C-88EE-4A07-80A5-10D1E9DEDB7C

Q37360367-36CE92D3-B8CA-4BF3-8719-F807170632F1

Q37360367-399AC4C5-64AE-4A2D-B42E-4BE8B99FB764

Q37360367-3B0406C0-3FDB-4DF2-9D4C-C37F24153E44

Q37360367-3CE73313-D731-480D-9E95-263D140CB5FC

Q37360367-433CC500-46B0-4DCC-937F-A9C1E516555A

Q37360367-60ED0EE0-4B8F-40BD-9380-110549F74188

Q37360367-68C16528-ECA1-493A-8DA8-A48ADFBD17C6

P2860

Q37360367-04431F0E-2472-4362-B319-D7295CE3765B

Q37360367-197E65D4-53EB-4549-8A35-C785402C862D

Q37360367-2072ED71-EB8A-4BD8-826C-76D23A2259D5

Q37360367-2FFED7C5-8579-411D-9D5F-310E0EEA9A61

Q37360367-40A4D6C3-14A6-405C-87DD-5504195D351C

Q37360367-593C5DCB-17FC-4945-9448-B066A73227C6

Q37360367-5A658880-7BE3-4395-8EEF-0289E8DB028F

Q37360367-5BC50C90-3795-4347-B78C-86723365020C

Q37360367-5C1147A7-7DCC-4852-A05B-4EA34F8F03B7

Q37360367-5FF12632-A1AE-4EAF-82F5-8FE9660059B4

P304

Q37360367-BF034BAE-A65E-4610-A88E-723FCE1DB322

P31

Q37360367-6CBCB150-B0BD-4C96-92EE-59FC0AD6E92F

P356

Q37360367-BB562096-E4AD-470B-8D53-144BF6F4C978

P407

Q37360367-880A0000-C0FC-411C-8D3B-55030DABAD3B

P433

Q37360367-35336042-8BEC-4296-81C0-1A6A03516E4D

P478

Q37360367-BC58B657-5185-490D-A81F-6E80F91B2845

P50

Q37360367-636B8B2F-D63F-43C4-98D4-BF10424C1B4F

Q37360367-8F06CE8E-66B8-4FFD-A40E-AFA7862B69EE

Q37360367-BF9A1B2C-0EEA-4BF1-8005-D57512848926

Q37360367-CB41017B-590E-4FD2-B21A-6BD78928DDB7

Q37360367-F0117708-A606-4075-83AC-F73C4605E8CD

P577

Q37360367-0F6704B5-7AEA-4F77-9930-87FE47F7C656

P5875

Q37360367-554F7491-D7A4-4CAE-983B-089A36016D03

P698

Q37360367-B9BAC038-E9E3-460C-8EB1-BF628B3FE850

P932

Q37360367-45677658-FB48-4FCC-9B49-F94E912CCFAB

P356

P1433

Journal of the National Cancer Institute

P1476

Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31.

@en

P2093

Ahwon Lee

http://www.w3.org/2001/XMLSchema#string

Charles E Geyer

http://www.w3.org/2001/XMLSchema#string

Chungyeul Kim

http://www.w3.org/2001/XMLSchema#string

D Lawrence Wickerham

http://www.w3.org/2001/XMLSchema#string

Debora Fumagalli

http://www.w3.org/2001/XMLSchema#string

Edward H Romond

http://www.w3.org/2001/XMLSchema#string

Eike Burandt

http://www.w3.org/2001/XMLSchema#string

Eleftherios P Mamounas

http://www.w3.org/2001/XMLSchema#string

Hanna Bandos

http://www.w3.org/2001/XMLSchema#string

Joseph P Costantino

http://www.w3.org/2001/XMLSchema#string

P2860

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

Direct multiplexed measurement of gene expression with color-coded probe pairs

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

Supervised risk predictor of breast cancer based on intrinsic subtypes

Side-population cells in luminal-type breast cancer have tumour-initiating cell properties, and are regulated by HER2 expression and signalling

Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer

Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action.

P304

1782-1788

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JNCI/DJT321

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

105

http://www.w3.org/2001/XMLSchema#string

P50

Sandra M. Swain

Zachary D Horne

Jong-Hyeon Jeong

Patrick G Gavin

P577

2013-11-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258827903

http://www.w3.org/2001/XMLSchema#string

P698

24262440

http://www.w3.org/2001/XMLSchema#string

P932

3848987

http://www.w3.org/2001/XMLSchema#string